# Protara Therapeutics, Inc.: overview TARA · Nasdaq · CIK 1359931 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tara.md) · [Financials](/companies/tara/financials.md) · [Filings](/companies/tara/filings.md) · [Insiders](/companies/tara/insiders.md) Latest reported revenue: [$0](/filings/0001171843-17-001555.md) for Q4 FY2014, three months to 2014-12-31, from the 10-K filed Mar 16, 2017 (XBRL us-gaap:Revenues, accession 0001171843-17-001555). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.50)](/filings/0001213900-25-107881.md) | not reported | [(0.29)](/filings/0001213900-26-055463.md) | [(0.35)](/filings/0001213900-26-087508.md) | [(0.31)](/filings/0001213900-25-107881.md) | not reported | [(0.31)](/filings/0001213900-26-055463.md) | [(0.36)](/filings/0001213900-26-087508.md) | | Free cash flow | $m | [(8.4) d](/filings/0001213900-25-107881.md) | [(9.3) d](/filings/0001213900-26-025433.md) | [(14.8)](/filings/0001213900-26-055463.md) | [(12.3) d](/filings/0001213900-26-087508.md) | [(12.5) d](/filings/0001213900-25-107881.md) | [(17.0) d](/filings/0001213900-26-025433.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(4.21)](/filings/0001213900-23-018373.md) | [(5.86)](/filings/0001213900-24-021982.md) | [(3.57)](/filings/0001213900-25-020368.md) | [(2.17)](/filings/0001213900-26-025433.md) | [(1.34)](/filings/0001213900-26-025433.md) | | Free cash flow | $m | [(35.1)](/filings/0001213900-23-018373.md) | [(26.6)](/filings/0001213900-24-021982.md) | [(37.6)](/filings/0001213900-25-020368.md) | [(35.9)](/filings/0001213900-26-025433.md) | [(56.5)](/filings/0001213900-26-025433.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tara/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $27.2m | 5,207,011 | | Not compared | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $17.9m | 4,696,709 | | Not compared | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $14.0m | 3,663,499 | | Added +268,531 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $11.8m | 3,101,166 | | Added +269,958 | | [Velan Capital Investment Management LP](/funds/1848809.md) | 2026-06-30 | $10.9m | 2,844,652 | | Added +10,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.8m | 2,300,133 | | Added +181,115 | | [Blackstone Inc.](/funds/1393818.md) | 2026-06-30 | $8.7m | 2,265,514 | | Unchanged | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $8.5m | 2,220,000 | | New +2,220,000 | | [Sio Capital Management, LLC](/funds/1482416.md) | 2026-06-30 | $7.3m | 1,921,872 | | Reduced −47,967 | | [ACORN CAPITAL ADVISORS, LLC](/funds/2054410.md) | 2026-06-30 | $6.7m | 1,752,115 | | Unchanged | ## Recent filings [All 802 filings](/companies/tara/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 08:10 ET | [10-Q](/filings/0001213900-26-087508.md) | Quarterly report, period 2026-06-30 | 0001213900-26-087508 | | 2026-08-11 | 08:05 ET | [8-K](/filings/0001213900-26-087506.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-087506 | | 2026-06-29 | 17:02 ET | [8-K](/filings/0001213900-26-073184.md) | 5.02 Departure or appointment of officers or directors | 0001213900-26-073184 | | 2026-06-15 | 16:05 ET | [8-K](/filings/0001213900-26-068774.md) | 5.07 Shareholder vote results | 0001213900-26-068774 | | 2026-05-13 | 08:10 ET | [10-Q](/filings/0001213900-26-055463.md) | Quarterly report, period 2026-03-31 | 0001213900-26-055463 | | 2026-05-13 | 08:05 ET | [8-K](/filings/0001213900-26-055462.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-055462 | | 2026-04-28 | 16:05 ET | [DEF 14A](/filings/0001213900-26-048536.md) | Proxy statement, period 2026-06-12 | 0001213900-26-048536 | | 2026-03-30 | 08:00 ET | [8-K](/filings/0001213900-26-035971.md) | 7.01 Regulation FD disclosure | 0001213900-26-035971 | | 2026-03-10 | 08:11 ET | [10-K](/filings/0001213900-26-025433.md) | Annual report, period 2025-12-31 | 0001213900-26-025433 | | 2026-03-10 | 08:06 ET | [8-K](/filings/0001213900-26-025432.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-025432 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-025433.md), filed Mar 10, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1359931 - Tickers: TARA - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.